Levosimendan: From basic science to clinical practice

Heart Failure Reviews

Volumn 14, Issue 4, 2009, Pages 265-275

  Parissis, John T ^a   Rafouli Stergiou, Pinelopi ^a   Paraskevaidis, Ioannis ^a   Mebazaa, Alexandre ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Calcium sensitizing agents; Inotropes; Pathophysiologic mechanisms; Prognosis

Indexed keywords

ACTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM SENSITIZER; CONTRACTILE PROTEIN; DOBUTAMINE; LEVOSIMENDAN; MYOSIN; PLACEBO; POTASSIUM CHANNEL; TROPONIN C;

ACUTE HEART FAILURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART OUTPUT; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; LONG TERM CARE; MORTALITY; PROGNOSIS; REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; DOBUTAMINE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; KIDNEY; MYOCARDIAL CONTRACTION; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PYRIDAZINES; QUALITY OF LIFE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 70449095204     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9128-4     Document Type: Review

References (69)

1. Gheorghiade M, Zannad F, Sopko G et al for International Working Group on Acute Heart Failure Syndromes (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112:3958-3968. doi: 10.1161/CIRCULATIONAHA.105.590091 (Pubitemid 43739494)
2. K Dickstein A Cohen-Solal G Filippatos, et al. 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 Eur J Heart Fail 10 933 989 10.1016/j.ejheart.2008.08.005 10.1016/j.ejheart.2008.08.005 18826876
3. J Parissis D Farmakis M Nieminen 2007 Classical inotropes and new cardiac enhancers Heart Fail Rev 12 149 156 10.1007/s10741-007-9014-5 10.1007/s10741-007-9014-5 17487580 (Pubitemid 46916961)
4. M Gheorghiade WT Abraham NM Albert, et al. 2006 Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2217 2226 10.1001/jama.296.18.2217 10.1001/jama.296.18.2217 17090768 (Pubitemid 44708052)
5. J Petersen M Felker 2008 Inotropes in the management of acute heart failure Crit Care Med 36 Suppl 106 111 10.1097/01.CCM.0000296273.72952.39
6. MA Munger 2006 Management of acute decompensated heart failure: treatment, controversy, and future directions Pharmacotherapy 26 131S 138S 10.1592/phco.26.8part2.131S 10.1592/phco.26.8part2.131S 16863479 (Pubitemid 44162831)
7. F Zannad C Adamopoulos A Mebazaa, et al. 2006 The challenge of acute decompensated heart failure Heart Fail Rev 11 135 139 10.1007/s10741-006-9484-x 10.1007/s10741-006-9484-x 16937032 (Pubitemid 44288728)
8. C Antoniades D Tousoulis N Koumallos, et al. 2007 Levosimendan: beyond its simple inotropic effect in heart failure Pharmacol Ther 114 184 197 10.1016/j.pharmthera.2007.01.008 10.1016/j.pharmthera.2007.01.008 17363065 (Pubitemid 46561532)
9. ++-sensitizers for the treatment of heart failure Curr Opin Crit Care 9 337 344 10.1097/00075198-200310000-00002 10.1097/00075198-200310000-00002 14508145 (Pubitemid 37204787)
10. M Tavares E Rezlan I Vostroknoutova, et al. 2008 New pharmacologic therapies for acute heart failure Crit Care Med 36 Suppl 112 120 10.1097/01.CCM.0000296810.74724.8D
11. P Pollesello Z Papp 2007 The Cardioprotective effects of levosimendan: preclinical and clinical evidence J Cardiovasc Pharmacol 50 257 263 10.1097/FJC.0b013e3180986230 17878752 (Pubitemid 47428972)
12. GJ Grover KD Garlid 2000 ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology J Mol Cell Cardiol 32 677 695 10.1006/jmcc.2000.1111 10.1006/jmcc.2000.1111 10756123 (Pubitemid 30658936)
13. AJ Kowaltowski S Seetharaman P Paucek, et al. 2001 Bioenergetic consequences of opening the ATP-sensitive K(+) channel of heart mitochondria Am J Physiol Heart Circ Physiol 280 H649 H657 11158963
14. Z Papp K Csaps P Pollesello, et al. 2005 Pharmacological mechanisms contributing to the clinical efficacy of levosimendan Cardiovasc Drug Rev 23 87 114
15. M Tavares A Andrade A Mebazaa 2008 Levosimendan use in several scenarios of acute heart failure Arq Bras Cardiol 90 211 215 10.1590/S0066- 782X2008000300012 10.1590/S0066-782X2008000300012 18392402
16. P Flevari JT Parissis D Leftheriotis, et al. 2006 Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy Am J Cardiol 98 12 1641 1645 10.1016/j.amjcard.2006.07.043 10.1016/j.amjcard.2006.07.043 17145226 (Pubitemid 44827973)
17. JG Cleland N Freemantle AP Coletta, et al. 2006 Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 105 110 10.1016/j.ejheart.2005.12.003 10.1016/j.ejheart.2005.12.003 16387630 (Pubitemid 43012109)
18. A Mebazaa MS Nieminen M Packer, et al. 2007 Levosimendan vs. dobutamine for patients with acute decompensated heart failure: SURVIVE Randomized Trial JAMA 297 1883 1891 10.1001/jama.297.17.1883 10.1001/jama.297.17.1883 17473298 (Pubitemid 46707842)
19. S Antila U Pesonen L Lehtonen, et al. 2004 Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators Eur J Pharm Sci 23 213 222 10.1016/j.ejps.2004.07.005 10.1016/j.ejps.2004.07.005 15489122 (Pubitemid 39369876)
20. F Follath JG Cleland H Just, et al. 2002 Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial Lancet 360 196 202 10.1016/S0140-6736(02)09455-2 10.1016/S0140-6736(02)09455-2 12133653 (Pubitemid 34804646)
21. VS Moiseyev P Poder N Andrejevs, et al. 2002 Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infraction. A randomized, placebo-controlled, double-blind study RUSSLAN Eur Heart J 23 1422 1432 10.1053/euhj.2001.3158 10.1053/euhj.2001.3158 12208222 (Pubitemid 36285574)
22. MS Nieminen J Akkila G Hasenfuss, et al. 2000 Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 1903 1912 10.1016/S0735-1097(00) 00961-X 10.1016/S0735-1097(00)00961-X 11092663 (Pubitemid 30844104)
23. MT Slawsky WS Colucci SS Gottlieb, et al. 2000 Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators Circulation 102 2222 2227 11056096
24. M Kivikko S Antila J Eha, et al. 2002 Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure J Clin Pharmacol 42 43 51 10.1177/0091270002042001005 10.1177/0091270002042001005 11808823 (Pubitemid 34038369)
25. M Kivikko S Antila J Eha, et al. 2002 Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure Int J Clin Pharmacol Ther 40 465 471 12395979 (Pubitemid 35153452)
26. J Lilleberg M Laine T Palkama, et al. 2007 Duration of the hemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure Eur J Heart Fail 9 75 82 10.1016/j.ejheart.2006.04.012 10.1016/j.ejheart.2006.04.012 16829185 (Pubitemid 46074480)
27. J Parissis A Karavidas V Bistola, et al. 2008 Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure Atherosclerosis 197 278 282 10.1016/j. atherosclerosis.2007.04.023 10.1016/j.atherosclerosis.2007.04.023 17568589 (Pubitemid 351284474)
28. JN Nanas P Papazoglou EP Tsagalou, et al. 2005 Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone Am J Cardiol 95 768 771 10.1016/j.amjcard.2004.11.033 10.1016/j.amjcard.2004.11.033 15757608 (Pubitemid 40332658)
29. J Parissis S Adamopoulos D Farmakis, et al. 2006 Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart 92 1768 1772 17105880
30. GC Fonarow WF Peacock TB Horwich ADHERE Scientific Advisory Committee Investigators, et al. 2008 Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE Am J Cardiol 101 2 231 237 10.1016/j.amjcard.2007.07.066 10.1016/j.amjcard.2007.07.066 18178412
31. J Parissis F Panou D Farmakis, et al. 2005 Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure Am J Cardiol 96 423 426 10.1016/j.amjcard.2005.03.092 10.1016/j.amjcard.2005.03.092 16054474 (Pubitemid 41058875)
32. K Maeda T Tsutamoto A Wada, et al. 2000 High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J Am Coll Cardiol 36 1587 1593 10.1016/S0735-1097(00)00912-8 10.1016/S0735-1097(00)00912-8 11079662 (Pubitemid 30825993)
33. Farmakis D, Parissis J, Bistola V et al (2008) Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol, (Oct), 28. Epub ahead of print
34. G Hasenfuss B Pieske M Castell, et al. 1998 Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium Circulation 98 2141 2147 9815868
35. S Adamopoulos J Parissis D Kremastinos 2001 A glossary of circulating cytokines in chronic heart failure Eur J Heart Fail 3 517 526 10.1016/S1388-9842(01)00156-8 10.1016/S1388-9842(01)00156-8 11595599 (Pubitemid 34619192)
36. S Adamopoulos J Parissis E Iliodromitis, et al. 2006 Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure Am J Cardiol 98 102 106 10.1016/j.amjcard.2006.01.068 10.1016/j.amjcard.2006.01.068 16784930 (Pubitemid 43902695)
37. J Parissis S Adamopoulos C Antoniades, et al. 2004 Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure Am J Cardiol 93 1309 1312 10.1016/j.amjcard.2004.01.073 10.1016/j.amjcard.2004.01.073 15135713 (Pubitemid 38595693)
38. M Keith A Geranmayegan MJ Sole, et al. 1998 Increased oxidative stress in patients with congestive heart failure J Am Coll Cardiol 31 1352 1356 10.1016/S0735-1097(98)00101-6 10.1016/S0735-1097(98)00101-6 9581732 (Pubitemid 28219127)
39. J Parissis I Andreadou S Markantonis, et al. 2007 Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure Atherosclerosis 195 e210 e215 10.1016/j.atherosclerosis. 2007.07.011 10.1016/j.atherosclerosis.2007.07.011 17707851 (Pubitemid 350087992)
40. P Pacher R Schulz L Liaudet, et al. 2005 Nitrosative stress and pharmacological modulation of heart failure Trends Pharmacol Sci 26 302 310 10.1016/j.tips.2005.04.003 10.1016/j.tips.2005.04.003 15925705 (Pubitemid 40733523)
41. G Zemljic M Bunc A Yazdanbakhsh, et al. 2007 Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation J Card Fail 13 417 421 10.1016/j.cardfail.2007.03.005 10.1016/j.cardfail.2007.03.005 17675054 (Pubitemid 47176926)
42. S Kurien KT Warfield CM Wood, et al. 2006 Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide Am J Cardiol 98 1627 1630 10.1016/j.amjcard.2006.07.044 10.1016/j.amjcard.2006.07.044 17145223 (Pubitemid 44827974)
43. MB Yilmaz K Yalta C Yontar, et al. 2007 Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine Cardiovasc Drugs Ther 21 431 435 10.1007/s10557-007-6066-7 10.1007/s10557-007-6066-7 17952581 (Pubitemid 350231513)
44. K Damman A Voors 2007 Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application Cardiovasc Drugs Ther 21 403 404 10.1007/s10557-007-6070-y 10.1007/s10557-007-6070-y 18030611 Editorial (Pubitemid 50004695)
45. H Tachibana HJ Cheng T Ukai, et al. 2005 Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure Am J Physiol Heart Circ Physiol 288 H914 H922 10.1152/ajpheart.00465. 2004 10.1152/ajpheart.00465.2004 15486041 (Pubitemid 40139680)
46. MM Givertz C Andreou CH Conrad, et al. 2007 Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships Circulation 115 1218 1224 17339544
47. H Haikala E Nissinen E Etemadzadeh, et al. 1995 Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation J Cardiovasc Pharmacol 25 794 801 10.1097/00005344-199505000-00016 10.1097/00005344-199505000-00016 7630157
48. J Lilleberg MS Nieminen J Akkila, et al. 1998 Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting Eur Heart J 19 660 668 10.1053/euhj.1997.0806 10.1053/euhj.1997.0806 9597417 (Pubitemid 28224690)
49. J Dernellis M Panaretou 2005 Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study Chest 128 2633 2639 10.1378/chest.128.4.2633 10.1378/chest.128.4.2633 16236936 (Pubitemid 41507621)
50. K Jorgensen O Bech-Hanssen E Houltz, et al. 2008 Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis Circulation 117 1075 1081 10.1161/CIRCULATIONAHA.107.722868 10.1161/ CIRCULATIONAHA.107.722868 18268152
51. J Parissis I Paraskevaidis V Bistola, et al. 2006 Effects of levosimendan on right ventricular function in patients with advanced heart failure Am J Cardiol 98 1489 1492 10.1016/j.amjcard.2006.06.052 10.1016/j.amjcard.2006.06.052 17126656 (Pubitemid 44779479)
52. H Kasikcioglu H Uyarel Z Tartan, et al. 2007 Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure? Int J Cardiol 118 246 248 10.1016/j.ijcard.2006.06.054 10.1016/j.ijcard.2006.06.054 17011057 (Pubitemid 46601652)
53. L De Luca P Proietti A Celotto, et al. 2005 Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infraction and left ventricular dysfunction Am Heart J 150 563 568 10.1016/j.ahj.2004.10.013 10.1016/j.ahj.2004.10.013 16169341 (Pubitemid 41317630)
54. JR Kersten MW Montgomery PS Pagel, et al. 2000 Levosimendan, a new positive inotropic drug, decreases myocardial infraction size via activation of K(ATP) channels Anesth Analg 90 5 11 10.1097/00000539-200001000-00003 10.1097/00000539-200001000-00003 10624967
55. L De Luca WS Colucci MS Nieminen BM Massie M Gheorghiade 2006 Evidence-based use of levosimendan in different clinical settings Eur Heart J 27 1908 1920 10.1093/eurheartj/ehi875 10.1093/eurheartj/ehi875 16682381 (Pubitemid 44297362)
56. I Ikonomidis J Parissis I Paraskevaidis, et al. 2007 Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure Eur J Heart Fail 9 1172 1177 10.1016/j.ejheart.2007.10. 002 10.1016/j.ejheart.2007.10.002 18062901 (Pubitemid 350138499)
57. AD Michaels B McKeown M Kostal, et al. 2005 Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake Circulation 111 1504 1509 10.1161/01.CIR.0000159252.82444.22 10.1161/01.CIR.0000159252.82444.22 15781741 (Pubitemid 40470645)
58. C Cianfrocca F Pelliccia A Auriti, et al. 2007 Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography Eur J Heart Fail 9 897 900 10.1016/j.ejheart.2007.05.003 10.1016/j.ejheart.2007.05.003 17572145 (Pubitemid 47332309)
59. J Parissis C Papadopoulos M Nikolaou, et al. 2007 Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients Cardiovasc Drugs Ther 21 263 268 10.1007/s10557-007-6034-2 10.1007/s10557-007- 6034-2 17610056 (Pubitemid 47387467)
60. W Jiang J Alexander E Christopher, et al. 2001 Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure Arch Intern Med 161 1849 1856 10.1001/archinte.161.15. 1849 10.1001/archinte.161.15.1849 11493126
61. KE Joynt DJ Whellan CM O'Connor 2004 Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure J Cardiac Fail 10 258 270 10.1016/j.cardfail.2003.09.008 10.1016/j.cardfail.2003.09.008 (Pubitemid 38869468)
62. JG Cleland A Takala M Apajasalo N Zethraeus G Kobelt, et al. 2003 Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial Eur J Heart Fail 5 1 101 108 10.1016/S1388-9842(02)00246-5 10.1016/S1388-9842(02)00246-5 12559222 (Pubitemid 36205551)
63. MT Oliveira Jr W Follador ML Martins, et al. 2008 Cost analysis of the treatment of acute decompensated heart failure Levosimendan versus dobutamine. Arquivos Brasileiros de Cardiologia 85 1 9 14
64. J Parissis D Farmakis V Bistola, et al. 2007 Levosimendan for the treatment of acute heart failure syndromes: Time to identify subpopulations of responding patients Am J Cardiol 99 146 147 10.1016/j.amjcard.2006.10.007 10.1016/j.amjcard.2006.10.007 17196480 (Pubitemid 44969358)
65. G Giannakoulas G Giannoglou V Vassilikos, et al. 2006 Clinical significance of acute neurohormonal response after levosimendan treatment Am J Cardiol 98 1123 1124 10.1016/j.amjcard.2006.07.007 10.1016/j.amjcard.2006.07.007 17027590 (Pubitemid 44486130)
66. P Bettencourt A Azevedo J Pimenta, et al. 2004 N-terminal-pro brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients Circulation 110 2168 2174 10.1161/01.CIR.0000144310.04433.BE 10.1161/01.CIR.0000144310.04433.BE 15451800 (Pubitemid 39372496)
67. P Bettencourt J Januzzi 2008 Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure Am J Cardiol 101 1 67A 71A 10.1016/j.amjcard.2007.11. 026 10.1016/j.amjcard.2007.11.026
68. D Kremastinos 2008 Acute heart failure: an old syndrome revisited Hellenic J Cardiol; HJC = Hellenike Kardiologike Epitheorese 49 199 200
69. J Parissis G Filippatos D Farmakis S Adamopoulos I Paraskevaidis D Kremastinos 2005 Levosimendan for the treatment of acute heart failure syndromes Expert Opin Pharmacother 6 15 2741 2751 10.1517/14656566.6.15.2741 10.1517/14656566.6.15.2741 16316312 (Pubitemid 41829451)